Mural Oncology Plc (MURA) Price & Analysis

Compare

435 Followers

MURA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.95 - $4.74

Previous CloseN/A

Volume157.34K

Average Volume (3M)172.75K

Market Cap

$28.76M

Enterprise Value-$31.23M

Total Cash (Recent Filing)$77.09M

Total Debt (Recent Filing)$5.17M

Price to Earnings (P/E)―

Beta-0.39

Next Earnings

Nov 12, 2025

EPS Estimate

-0.59

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.78

Shares Outstanding17,324,360

10 Day Avg. Volume360,116

30 Day Avg. Volume172,748

Financial Highlights & Ratios

PEG Ratio0.01

Price to Book (P/B)0.39

Price to Sales (P/S)0.00

P/FCF Ratio-0.42

Enterprise Value/Market Cap-1.09

Enterprise Value/Revenue-8.94

Enterprise Value/Gross Profit-17.89

Enterprise Value/Ebitda0.31

Forecast

1Y Price Target

$6.00

Price Target Upside261.45% Upside

Rating ConsensusHold

Number of Analyst Covering0

Bulls Say, Bears Say

Bulls Say

Data UpdatesThe company remains on track for data updates from Phase 2 ARTISTRY-6 in mucosal melanoma, with a focus on positive outcomes.

Future OpportunitiesMural's next catalyst is Phase 2 mucosal melanoma data, potentially providing a new opportunity for success.

Potential Regulatory ApprovalMURA believes an objective response rate of 20-25% would be a meaningful outcome and would support a discussion with FDA on a BLA submission for accelerated approval.

Bears Say

Clinical DevelopmentMURA announced its decision to discontinue clinical development of nemvaleukin.

Survival AnalysisThe interim analysis of the Phase 3 ARTISTRY-7 study failed to show a statistically significant overall survival benefit over investigator’s choice chemotherapy in platinum-resistant ovarian cancer.

Workforce ReductionThe company will undertake a reduction in its employee workforce of approximately 90%.

Mural Oncology Plc News

Mural Oncology reports Q2 EPS ($2.78) vs ($1.86) last year

Following its announcement on April 15, 2025, Mural has taken steps to conserve its remaining cash, including the...

11d ago

MURA

Mural Oncology Plc Elects Directors at Annual Meeting

An update from Mural Oncology Plc ( ($MURA) ) is now available. On June 11, 2025, Mural Oncology...

2M ago

MURA

MURA Upcoming Earnings Report: What to Expect?

Mural Oncology Plc (MURA) is scheduled to report 1st quarter earnings on 05/20/2025. Regarding Q1 estimates, Wall Street...

3M ago

MURA

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Mural Oncology PLC (MURA)...

4M ago

QID

AISP

Unusually active option classes on open April 21st

Unusual total active option classes on open include: Mural Oncology PLC (MURA), General Electric (GE), Barrick Gold (GOLD),...

4M ago

AMC

Mural Oncology to discontinue nemvaleukin development, reduce staff by 90%

Mural Oncology (MURA) announced that following review of data from its phase 2 ARTISTRY-6 trial in melanoma and...

4M ago

MURA

Mural Oncology plans to explore strategic alternatives

Mural plans to explore potential strategic alternatives including, but not limited to, an offer for or other acquisition...

4M ago

MURA

Mural Oncology price target lowered to $6 from $18 at H.C. Wainwright

H.C. Wainwright analyst Andres Maldonado lowered the firm’s price target on Mural Oncology (MURA) to $6 from $18...

5M ago

MURA

Mural Oncology halting progress of nemvaleukin trial in ovarian cancer

Mural Oncology (MURA) announced that the ARTISTRY-7 phase 3 trial of nemvaleukin alfa in combination with Merck’s (MRK)...

5M ago

MRK

MURA

Mural Oncology downgraded to Hold from Buy at JonesResearch

JonesResearch downgraded Mural Oncology (MURA) to Hold from Buy without a price target after the company’s interim survival...

5M ago

MURA

Mural Oncology downgraded to Outperform from Strong Buy at Raymond James

Raymond James analyst Laura Prendergast downgraded Mural Oncology (MURA) to Outperform from Strong Buy with an $18 price...

5M ago

MURA

Raymond James downgrades Mural Oncology after ovarian cancer failure

Raymond James downgraded Mural Oncology (MURA) to Outperform from Strong Buy with a price target of $6, down...

5M ago

MURA

Promising Developments in Mural Oncology Plc’s ARTISTRY-7 Trial Boost Buy Rating

Analyst Soumit Roy of JonesTrading maintained a Buy rating on Mural Oncology Plc (MURA – Research Report), retaining...

5M ago

MURA

Promising Outlook for Mural Oncology: Buy Rating Driven by Nemvaleukin’s Potential and Strategic Trials

In a report released today, Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Mural Oncology...

5M ago

MURA

MURA FAQ

What was Mural Oncology Plc’s price range in the past 12 months?

Mural Oncology Plc lowest stock price was $0.95 and its highest was $4.74 in the past 12 months.

What is Mural Oncology Plc’s market cap?

Mural Oncology Plc’s market cap is $28.76M.

When is Mural Oncology Plc’s upcoming earnings report date?

Mural Oncology Plc’s upcoming earnings report date is Nov 12, 2025 which is in 89 days.

How were Mural Oncology Plc’s earnings last quarter?

Mural Oncology Plc released its earnings results on Aug 04, 2025. The company reported -$2.78 earnings per share for the quarter, missing the consensus estimate of -$1 by -$1.78.

Is Mural Oncology Plc overvalued?

According to Wall Street analysts Mural Oncology Plc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Mural Oncology Plc pay dividends?

Mural Oncology Plc does not currently pay dividends.

What is Mural Oncology Plc’s EPS estimate?

Mural Oncology Plc’s EPS estimate is -0.59.

How many shares outstanding does Mural Oncology Plc have?

Mural Oncology Plc has 17,324,360 shares outstanding.

What happened to Mural Oncology Plc’s price movement after its last earnings report?

Mural Oncology Plc reported an EPS of -$2.78 in its last earnings report, missing expectations of -$1. Following the earnings report the stock price went down -20.259%.

Which hedge fund is a major shareholder of Mural Oncology Plc?

Currently, no hedge funds are holding shares in MURA

Mural Oncology Plc Stock Smart Score

Underperform

Fundamentals

Return on Equity

-111.75%

Trailing 12-Months

Asset Growth

-62.73%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Mural Oncology Plc

Mural Oncology Plc (MURA) is a biotechnology company focused on the development and commercialization of innovative cancer therapies. Operating within the pharmaceutical and healthcare sectors, Mural Oncology is dedicated to researching and delivering cutting-edge treatments that address unmet needs in oncology. The company's core products include targeted therapies and immuno-oncology treatments designed to improve patient outcomes and quality of life for those battling various forms of cancer.